Fenwick represented Elevation Oncology (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, in its initial public offering of 6,250,000 shares of its common stock at a public offering price of $16 per share.
The shares began trading on the Nasdaq Global Market on June 25, 2021, under the ticker symbol “ELEV.” J.P. Morgan Securities, Cowen, and SVB Leerink acted as joint bookrunning managers for the offering. Wedbush PacGrow acted as lead manager for the offering. More information can be obtained from the company's announcement.
The Fenwick transaction team included corporate partners Effie Toshav, Robert Freedman and Julia Forbess and associates Ryan Mitteness, Kristen Nicol, Arielle Trapp and Anja Kong; executive compensation and employee benefits partner Marshall Mort and associates Jonathan Stephenson and Cynthia Yuan; and tax partner William Skinner.